<DOC>
	<DOC>NCT00686803</DOC>
	<brief_summary>The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous (SC) PL-3994, relative to placebo in subjects with controlled hypertension. Including in this evaluation is the effect PL3994 has on blood pressure.</brief_summary>
	<brief_title>Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension</brief_title>
	<detailed_description>Uncontrolled hypertension, including both hypertensive urgency and hypertensive emergency, is commonly seen in emergency rooms and other urgent care settings. Current standards of care include intravenously administered drugs, which can be difficult to titrate and require ongoing monitoring. This study examines the effect of PL-3994 on patients with controlled hypertension who are receiving antihypertensive medications.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Subjects must have had a diagnosis of essential hypertension for at least 1 year, per subject verbal history Subject must be on a stable dose of at least one, but not more than 3 antihypertensive medications for at least 3 months, per subject verbal history. Subject must have a systolic blood pressure at screening between 100 and 150 mmHg, and diastolic blood pressure must not exceed 105 mmHg. Subject weight greater than 100 kg or less than 50 kg. Any significant medical condition or abnormal safety laboratory results which, in the judgement of the Investigator would place the subject at significant risk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>hypertension</keyword>
	<keyword>controlled hypertension</keyword>
	<keyword>hypertensives</keyword>
</DOC>